Bluebird, Celgene to share US costs, profits on lead cancer CAR-T – FierceBiotech
FierceBiotech |
Bluebird, Celgene to share US costs, profits on lead cancer CAR–T
FierceBiotech Bluebird bio has pulled the trigger on an option to co-develop and co-promote the anti-BCMA CAR-T treatment, bb2121, with Celgene in the U.S. The move comes two years after Celgene forked over $10 million to exclusively license the therapy. The pair … Celgene Shares Higher on Co-Development Pact With Bluebird |
